TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02102230

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia Plus Mobile App (CBT-I-MA)
Description: This is a mobile-app-augmented, group-delivered version of the six-session Cognitive-Behavioral Treatment for Insomnia that has been disseminated throughout the VA. It incorporates psychoeducation, diary-based sleep assessment, estimation of sleep scheduling and efficiency, evaluation/mitigation of dysfunctional sleep-related beliefs/ behaviors, generation of sleep prescription (typically restriction), iterative review of sleep efficiency and prescription, and planning for maintenance of gains. The mobile-app augmentation substitutes a smartphone-based sleep diary with time-stamping of records to mitigate the common postponement of diary recording and consequent loss of validity. The app also records the sleep prescription, making it, along with links to web-based psychoeducational materials, easily accessible to users. The app also provides plots of bed times, wake times, and sleep efficiency over time, with the goal of promoting adherence.
Study: NCT02787798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan/sacubitril 200 mg
Description: Treatment with 200 mg tablets during 2 to 4 weeks
Study: NCT02102230

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Desensitization Treatment for Insomnia
Description: This is a group-delivered version of the sham sleep improvement treatment developed by Edinger which purports to desensitize the patient to the various aspects of the sleep experience which are presented as distressing.
Study: NCT02787798

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Microneurography
Description: Microneurography recording of sympathetic nervous system activity in muscle destiny

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microneurography
Description: Microneurography recording of sympathetic nervous system activity in muscle destiny
Study: NCT01730976

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D 2,000 I.U.
Study: NCT03545581

Intervention type: OTHER
Group type: OTHER
Intervention: Experimental diet Fru rich diet
Description: 7 days (day 1 to day 7) with fructose enriched drinks 3x/d. Test meal at day 7 with fructose (0.7 g/body weight) and glucose (0.7 g/body weight)

Intervention type: OTHER
Group type: OTHER
Intervention: Experimental low Fru diet
Description: 7 days (day 1 to day 7) with low-fructose diet (\<10g/d). Test meal at day 7 with fructose (0.7 g/body weight) and glucose (0.7 g/body weight)
Study: NCT02645162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based Preschool
Description: * Preschool sessions in community-based preschool~* Run by trained community youth leaders from the same village.
Study: NCT00502515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR180575
Description: Oral, once daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR180575
Description: Oral, once daily dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, once daily dosing
Study: NCT01129895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health promotion
Description: In each intervention clinic 5 workshops on the initiation of health prevention projects in each clinic will be organized by the intervention team and than the clinic will be followed by the intervention team for 6 months.
Study: NCT01412983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb Test lens
Description: Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ciba Vision soft contact lens
Description: Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.
Study: NCT02569242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel/Paclitaxel
Study: NCT03088462

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial treatment
Description: Any psychosocial treatment participant is involved in such as individual therapy, group therapy, or support groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LiveWell Program
Description: Participants work with a health coach to facilitate use of a smartphone application designed for people with bipolar disorder.
Study: NCT03663738

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mobile app NOVAME
Description: The training program is divided into 3 periods of 21 days, where each day the patient receives a new formation pill. At the end of one of these periods there will be a week of review in which the patient will receive reminders of the contents that he has already received. These pills will help the patient to acquire healthy lifestyle habits and improve the control of the disease. The length of the program is 84 days, and once completed, the patient can repeat or intensify efforts in the areas he considers and continue to have access to the virtual coach. Patients assigned to the intervention group will receive a brief structured explanation on how to use the application and its contents.
Study: NCT04814901

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Curing small and medium sized oronasal fistula
Description: * Flap will be marked medial to the duct, which limits posterior extent of flap. Anterior flap marking starts 1cm posterior to oral commissure.~* Width of flap was kept to about 2-2.5cm.~* An initial incision will be made 1cm posterior to oral commissure.~* Incision will be deepened through buccal mucosa, submucosa, \& underlying muscles into layer of buccal fat.~* Flap will be dissected in a retrograde or antegrade manner depending on fistula site, maintaining vessels in a central position in the flap.~* Once completely raised, flap inserted \& sutured in place while donor site be closed primarily with 4-0 polyglactin (Vicryl) interrupted sutures.~* Patient's comparator group will be treated by raising a palatal pedicled flap.~* Flap will be outlined extending from palatal mucosa against permanent 2nd molar till permanent canine anteriorly.~* It is rotated towards oronasal fistula \& secured in place using 4 -0 Vicryl interrupted sutures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Curing small and medium sized oronasal fistula
Description: * Flap will be marked medial to the duct, which limits posterior extent of flap. Anterior flap marking starts 1cm posterior to oral commissure.~* Width of flap was kept to about 2-2.5cm.~* An initial incision will be made 1cm posterior to oral commissure.~* Incision will be deepened through buccal mucosa, submucosa, \& underlying muscles into layer of buccal fat.~* Flap will be dissected in a retrograde or antegrade manner depending on fistula site, maintaining vessels in a central position in the flap.~* Once completely raised, flap inserted \& sutured in place while donor site be closed primarily with 4-0 polyglactin (Vicryl) interrupted sutures.~* Patient's comparator group will be treated by raising a palatal pedicled flap.~* Flap will be outlined extending from palatal mucosa against permanent 2nd molar till permanent canine anteriorly.~* It is rotated towards oronasal fistula \& secured in place using 4 -0 Vicryl interrupted sutures.
Study: NCT00710437

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: Steady state infusion 0.007 mcg/kg/min

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: Steady state infusion 0.007 mcg/kg/min
Study: NCT01270867

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Thrombectomy
Description: Each arm will use either Merci or Trevo as the primary Mechanical Thrombectomy device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy
Description: Each arm will use either Merci or Trevo as the primary Mechanical Thrombectomy device.
Study: NCT01117350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: 100 Units/mL solution for injection in a pre-filled SoloStar pen
Study: NCT02035423

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 120 IU milk
Description: Daily consumption of milk fortified with 120 IU vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 120 IU milk
Description: Daily consumption of milk fortified with 120 IU vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 120 IU milk
Description: Daily consumption of milk fortified with 120 IU vitamin D
Study: NCT01117350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: 6 mg/mL solution for injection in a 3-mL pre-filled pen (18mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin was a background treatment, mandatory for each patient randomized in the study (at the minimum dose of 1g/day). It was not supplied by the sponsor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin was a background treatment, mandatory for each patient randomized in the study (at the minimum dose of 1g/day). It was not supplied by the sponsor.
Study: NCT03806257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Physical Therapy Protocol
Description: A structured physical therapy protocol that requires subject to ambulate more frequently than the standard-of-care patient.
Study: NCT03958487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video feedback, Feedback online
Description: The treatment phase have 3 timepoints, 1 the patient is asked to perform an ADL alone, 2. Video feedback is administrated. This requires the participant to watch its own videotaped performance with the therapist while the therapist encourage the participant to identify errors, areas of strength, and to suggest strategies to solve errors in future sessions. 3. feedback online will be provided by the therapist on participant performance. The therapist will wait for the patient to detect and correct their error spontaneously. If the patient does not detect it, the therapist provides unspecified/specific help. This strategy is based on previous work (Schmidt, et al 2013, Ownstorth et al. 2010). The novelty of our procedure is the inclusion of distracting and conflicting/problem solving situations to be inhibited, detected and solved. Feedback will focus on these situations. The level of monitoring requirements will be adjusted to participants performance using a changing criterion design.
Study: NCT04134312

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Brachyury
Description: MVA-BN-Brachyury will be administered intravenously every three weeks with three administrations in total at the dose indicated by the enrolled cohort.
Study: NCT01219075

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy isoflavones
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Correlative studies

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: magnetic resonance imaging
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: biopsy
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02035423

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 120 IU milk
Description: Daily consumption of milk fortified with 120 IU vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 200 IU Milk
Description: Daily Consumption of milk fortified with 200 IU vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 200 IU Milk
Description: Daily Consumption of milk fortified with 200 IU vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 200 IU Milk
Description: Daily Consumption of milk fortified with 200 IU vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 200 IU Milk
Description: Daily Consumption of milk fortified with 200 IU vitamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-Fortified Milk
Description: Daily consumption of non-fortified milk

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-Fortified Milk
Description: Daily consumption of non-fortified milk

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-Fortified Milk
Description: Daily consumption of non-fortified milk

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-Fortified Milk
Description: Daily consumption of non-fortified milk
Study: NCT04133324

Intervention type: DIAGNOSTIC_TEST
Intervention: C-reactive protein
Description: C-reactive protein at postoperative days four and two.
Study: NCT03170284

Intervention type: DRUG
Intervention: Bevacizumab
Description: Bevacizumab is prescribed by physicians as per SPC.
Study: NCT01236885

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer-assisted intervention
Description: Undergo blood glucose management using Glucommander
Study: NCT03937986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: The pharmacodynamic effects of suvorexant maintenance will be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: The pharmacodynamic effects of suvorexant maintenance will be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: The pharmacodynamic effects of suvorexant maintenance will be determined.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and suvorexant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and suvorexant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and suvorexant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine
Description: The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and suvorexant.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The pharmacodynamic effects of placebo will be determined.
Study: NCT03668548

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine
Description: 192 mg/kg body mass/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A taste and calorie-matched placebo
Study: NCT02348567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unannounced hospital surveys
Description: This is a cluster-randomised controlled trial performed at hospital level. We hypothesise that unannounced surveys produce less successful assessments of patient safety compared to announced surveys (conventional/control). This study defines less successful as less compliance with the included standards and performance indicators.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: announced hospital surveys
Study: NCT03172650

Intervention type: DIAGNOSTIC_TEST
Intervention: glomerular filtration rate
Description: collection of blood sample 5 milliliter for calculation of glomerular filtration rate

Intervention type: DIAGNOSTIC_TEST
Intervention: glomerular filtration rate
Description: collection of blood sample 5 milliliter for calculation of glomerular filtration rate
Study: NCT03219125

Intervention type: DEVICE
Intervention: Dixon Magnetic Resonance Imaging
Description: MRI of the lumbar spine (L1 to L4) and hip (non-dominant) for the measurement of Ad Med. (In%) by the DIXON sequence.

Intervention type: DEVICE
Intervention: dual-energy X-ray absorptiometry (DXA)
Description: Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
Study: NCT03244371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood draw
Description: 4 blood draws of 25 mls of blood will be performed at 4 differents time points (before treatment, 4 weeks later, at the end of the treatment and 6 months after the end of the treatment)
Study: NCT00844246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Developmental screening using ASQ and MCHAT
Description: In the SRS intervention arm subjects will complete developmental screening tools with a school readiness specialist at their 9, 18, 24 and 30 month well child visits and then complete their well child visit with their primary care clinician to discuss the results.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Developmental screening using ASQ and MCHAT
Description: Subjects who are randomized to PCP arm will be screened for developmental delays by their Primary Care Clinician at their 9, 18, 24 and 30 month well child visits. The corresponding screening tools may be mailed to the study participants 2 weeks before the scheduled well child visits. Those who do not complete the screening tools or those who did not receive them in the mail will then complete the questionnaire in the office prior to seeing their doctor or with their doctor. The PCP will then score the screening tool and interpret the test results. Developmental counseling and/or anticipatory guidance will be provided, as per usual care. EI referral will be completed, at the discretion of the provider with the approval of the caregiver , if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
Study: NCT02185599

Intervention type: DEVICE
Intervention: DySIS
Description: Colposcopy performed with the DySIS digital colposcope
Study: NCT03711448

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone treatment
Description: tapering prednisone regimen
Study: NCT01200511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL
Description: Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
Study: NCT01791439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lidocaine
Description: Application of lidocaine to the glossopharyngeal nerve.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02768129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: active stimulation: 2 milliamp (mA), 20 mins

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: sham stimulation
Study: NCT03352856

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Barley starch
Description: Highly purified barley starch

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maize starch
Description: Maize starch
Study: NCT02623361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Nerve Block
Description: Regional Anesthesia by Local Anesthetic Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham Block
Description: Sham Block by saline injection
Study: NCT03894540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPN60090
Description: Oral capsules given daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPN60090
Description: Oral capsules given daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPN60090
Description: Oral capsules given daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: An intravenous solution in single-use vial to be diluted for infusion.
Study: NCT03711448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone and ustekinumab treatment
Description: Treatment with prednisone and ustekinumab (90 mg subcutaneously at inclusion (W0), W4, W16 and W28)
Study: NCT03894540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: An intravenous solution in single-use vial to be diluted for infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPN60090 single administration
Description: Oral capsules given once
Study: NCT04381000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: The group follows warm up exercise (maximum 10 minutes). This consisted of combined, breathing techniques, low-impact aerobic exercises, free range of motion exercises of upper and lower limbs and spine, and coordination-based exercises of hands and feet. Breathing techniques take regular activities such as sitting, walking, and lying down. At the end of this phase, active stretching exercises of major muscles of arm, leg and trunk were performed.
Study: NCT04711421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 VIVOFIT-
Description: Feedback on number of steps taken by patint, as recorded by pedometers, provided by research team
Study: NCT03450850

Intervention type: DEVICE
Group type: OTHER
Intervention: NOVOTTF-200A
Description: NOVOTTF-200A will be administered under appropriate guidelines. Monthly adherence rate \>= 75% (\>= 18 hours/day) over a 4-week cycle (28 days) will be strongly encouraged.
Study: NCT03455543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Provant Therapy System
Description: Treatment with active Provant Therapy System

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive (sham) Provant Therapy System
Description: Treatment with inactive Provant Therapy System